

## Data Sharing Statement

<b>Article Info</b>	<a href="https://dx.doi.org/10.21037/atm-21-4012">https://dx.doi.org/10.21037/atm-21-4012</a>	
<b>Item</b>	<b>Question</b>	<b>Authors' Response (place "-" if not applicable)</b>
1	Would you like to share data collected for your study to others?	Yes
2	If not, would you like to share the reason for your decision?	-
3	What data in particular will be shared?	TLR2 inhibition could significantly ameliorate PA-induced and LPS-amplified lipid accumulation, inflammatory, and cell apoptosis, it had no significant effect on L02 cells treated with LPS alone.
4	Any other documents will be shared? Such as study protocol, statistical analysis plan, informed consent form, clinical study report, analytic code.	Statistical analysis plan, informed consent form, and clinical study report will also be shared if requested.
5	When will data availability begin?	From the publication date.
6	When will data availability end?	One years within the publication date.
7	To whom will you share the data?	People who are interested in NAFLD.
8	For what type of analysis or purpose?	Used to analyze NAFLD.
9	How or where can the data/documents be obtained?	Emails could be sent to the address below to obtain the shared data: lcheneye@163.com.
10	Any other restrictions?	We may balance the potential benefits and risks for each request and then provide the data that could be shared.